» Articles » PMID: 27015666

Tumors of the Sublingual Gland: a National Clinicopathologic Study of 29 Cases

Overview
Date 2016 Mar 27
PMID 27015666
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors of the salivary glands are a heterogeneous group of diseases most often originating in the major salivary glands. Only a minor proportion of mainly malignant tumors arise in the sublingual gland. Due to the rarity of sublingual gland tumors (SGTs), little is known about the clinicopathologic characteristics, prognostic factors, and clinical course. We present a large national series of histopathologically revised SGTs from the past 35 years in Denmark with clinicopathologic correlation. Twenty nine cases were identified, of which 96.6 % were malignant and 16/28 (57.1 %) were adenoid cystic carcinomas (ACC). Patient demography was similar to salivary gland tumors in other locations. All fine needle aspiration cytologies (FNACs) interpreted as benign were from ACCs. Metastatic disease was found in 12.5 % of ACCs at diagnosis with one third of all ACC patients having metastases at the end of follow-up. Stage >II and T-stage >2 were significantly associated with shortened disease-specific survival (DSS) (p = 0.005 and <0.001, respectively), whereas perineural invasion and involved margins was not. No parameters were associated with disease-free survival. In conclusion, the majority of SGTs are malignant, most frequently ACC with a high rate of metastatic spread. The diagnostic value of FNAC in SGTs seems inferior to what is found for other major salivary glands. DSS is determined by stage and T-stage and not by histopathological parameters. International collaboration is warranted to confirm and elaborate these findings in larger materials.

Citing Articles

Are dental professionals aware of the discovery of newly identified salivary glands? Is there a debate about this discovery?.

Karabiyik A, Sumer T, Cam K, Ucak Semirgin S, Zengin A Clin Oral Investig. 2025; 29(3):161.

PMID: 40011231 DOI: 10.1007/s00784-025-06228-1.


Prognostic factors for sublingual gland carcinoma: a population-based Surveillance, Epidemiology and End Results database study.

Qin G, Wu L, Li C, Zhang Q, An Z, Qin J J Int Med Res. 2023; 51(11):3000605231187940.

PMID: 37944187 PMC: 10637180. DOI: 10.1177/03000605231187940.


Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer.

Veneroni M, Festa B, Costantino A, Spriano G, Mercante G, De Virgilio A Head Neck Pathol. 2023; 17(2):515-527.

PMID: 36723850 PMC: 10293532. DOI: 10.1007/s12105-023-01528-y.


Lymphomas Affecting the Sublingual Glands: A Clinicopathological Study.

de Araujo G, Morais-Perdigao A, de Caceres C, Lopes M, Aguirre-Urizar J, Carlos R Head Neck Pathol. 2022; 17(1):154-164.

PMID: 36166159 PMC: 10063706. DOI: 10.1007/s12105-022-01489-8.


Diagnosis and management of malignant sublingual gland tumors: a narrative review.

Park M, Cho J, Ryu J, Jeong H Gland Surg. 2022; 10(12):3415-3423.

PMID: 35070901 PMC: 8749102. DOI: 10.21037/gs-21-620.


References
1.
Nichols C, Geist R, Nichols K . Clear cell neoplasm. J Laryngol Otol. 1992; 106(6):553-5. DOI: 10.1017/s0022215100120122. View

2.
Kobayashi I, Kiyoshima T, Ozeki S, Shima K, Shigemura N, Matsuo K . Immunohistochemical and ultrastructural study of a papillary cystadenocarcinoma arising from the sublingual gland. J Oral Pathol Med. 1999; 28(6):282-6. DOI: 10.1111/j.1600-0714.1999.tb02040.x. View

3.
Coca-Pelaz A, Rodrigo J, Bradley P, Vander Poorten V, Triantafyllou A, Hunt J . Adenoid cystic carcinoma of the head and neck--An update. Oral Oncol. 2015; 51(7):652-61. DOI: 10.1016/j.oraloncology.2015.04.005. View

4.
Suzuki H, Henderson R . Acinic cell carcinoma of the sublingual gland. Arch Otolaryngol. 1968; 87(2):146-9. DOI: 10.1001/archotol.1968.00760060148009. View

5.
SPIRO R . Treating tumors of the sublingual glands, including a useful technique for repair of the floor of the mouth after resection. Am J Surg. 1995; 170(5):457-60. DOI: 10.1016/s0002-9610(99)80329-8. View